Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease

Experimental Neurology

Volumn 269, Issue , 2015, Pages 133-141

  Concannon, Ruth M ^a   Okine, Bright N ^a   Finn, David P ^a   Dowd, Eilís ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

CB2 receptors; Endocannabinoid system; Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; OXIDOPAMINE; CANNABINOID 1 RECEPTOR; CNR2 PROTEIN, RAT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CB2 RECEPTOR GENE; CONTROLLED STUDY; CORPUS STRIATUM; EXPERIMENTAL BEHAVIORAL TEST; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOTOR DYSFUNCTION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DISEASE MODEL; INFLAMMATION; METABOLISM; NERVE DEGENERATION; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; INFLAMMATION; MALE; NERVE DEGENERATION; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 84928331924     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.04.007     Document Type: Article

References (53)

1. 2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 2007, 5:73.
2. 2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
3. 2 receptor. J. Neurosci. Methods 2013, 216:87-95.
4. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 2003, 23:11136-11141.
5. 2 receptors in human brain inflammation. Br. J. Pharmacol. 2008, 153:277-285.
6. Burke N.N., Kerr D.M., Moriarty O., Finn D.P., Roche M. Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav. Immun. 2014, 42:147-156.
7. Burstein S.H., Zurier R.B. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009, 11:109-119.
8. Choi D.-Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., Shin E.-J., Kim H.-C., Gash D.M., Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 2009, 4:e5482.
9. Cicchetti F., Brownell A., Williams K., Chen Y., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 2002, 15:991-998.
10. Concannon R.M., Finn D.P., Dowd E. Cannabinoids in Parkinson's disease. Cannabinoids In Neurologic And Mental Disease 2015, Elsevier, San Diego, USA. L. Fattore (Ed.).
11. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., Del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 2003, 18:2731-2742.
12. 2) suppresses microglial activation. J. Neuroinflammation 2005, 2:29.
13. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
14. Esposito E., Impellizzeri D., Mazzon E., Paterniti I., Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 2012, 7:e41880.
15. 125I] SD7015. Brain Res. Bull. 2012, 87:504-510.
16. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156:1029-1040.
17. Ford G.K., Kieran S., Dolan K., Harhen B., Finn D.P. A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. Pain 2011, 152:2495-2504.
18. Ford G., Moriarty O., Okine B., Tully E., Mulcahy A., Harhen B., Finn D. Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats. Eur. J. Pain 2015.
19. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
20. Gonzalez-Aparicio R., Blanco E., Serrano A., Pavon F.J., Parsons L.H., Maldonado R., Robledo P., Fernandez-Espejo E., De Fonseca F.R. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. Int. J. Neuropsychopharmacol. 2013, 1-14.
21. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A., Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 2002, 22:6900-6907.
22. Hansen H.S. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp. Neurol. 2010, 224:48-55.
23. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
24. Hoban D.B., Connaughton E., Connaughton C., Hogan G., Thornton C., Mulcahy P., Moloney T.C., Dowd E. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav. Immun. 2013, 27:91-100.
25. 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 2003, 110:1279-1288.
26. Kerr D., Burke N., Ford G.K., Connor T., Harhen B., Egan L., Finn D.P., Roche M. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 204:53-63.
27. Kerr D., Harhen B., Okine B., Egan L., Finn D., Roche M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br. J. Pharmacol. 2013, 169:808-819.
28. 2 receptor. Br. J. Pharmacol. 2003, 139:775-786.
29. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 2001, 14:1827-1832.
30. Mcgeer P., Itagaki S., Boyes B., Mcgeer E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
31. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 2003, 23:6470-6474.
32. 2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 2002, 67:829-836.
33. Munro S., Thomas K.L., Abu-Shaar M. Molecular Characterization Of A Peripheral Receptor For Cannabinoids 1993.
34. Okine B., Rea K., Olango W., Price J., Herdman S., Madasu M., Roche M., Finn D. A role for PPARα in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. Br. J. Pharmacol. 2014, 171:1462-1471.
35. Olango W., Roche M., Ford G.K., Harhen B., Finn D.P. The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. Br. J. Pharmacol. 2012, 165:2549-2560.
36. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
37. 2 cannabinoid receptor controls myeloid progenitor trafficking involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 2008, 283:13320-13329.
38. 2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
39. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanuš L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
40. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agrò A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 2005, 57:777-779.
41. Pisani V., Moschella V., Bari M., Fezza F., Galati S., Bernardi G., Stanzione P., Pisani A., Maccarrone M. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov. Disord. 2010, 25:920-924.
42. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernandez E., Strong J.R., Lutz B., Marsicano G., Roberts J.L. WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the MPTP mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:2177.
43. Ramírez B.G., Blázquez C., Del Pulgar T.G., Guzmán M., De Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
44. Rea K., Olango W.M., Okine B.N., Madasu M.K., Mcguire I.C., Coyle K., Harhen B., Roche M., Finn D.P. Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 2014, 155:69-79.
45. 2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals 2010, 3:2517-2553.
46. 2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009, 57:1154-1167.
47. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
48. Scotter E.L., Abood M.E., Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 2010, 160:480-498.
49. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
50. Van Laere K., Casteels C., Lunskens S., Goffin K., Grachev I.D., Bormans G., Vandenberghe W. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol. Aging 2012, 33:620.e1-620.e8.
51. 1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res. Bull. 2010, 81:543-548.
52. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
53. 2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab. 2007, 27:1387-1396.